Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 1991BloodOpen Access

Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAliza AckersteinSheba Medical CenterEKEli KedarHebrew University of JerusalemSSS SlavinN. I. Lobachevsky State University of Nizhny Novgorod

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ackerstein et al. (1991) studied this question.

synapsesocial.com/papers/6a710bc8a528af2d65c3e0f6https://doi.org/10.1182/blood.v78.5.1212.1212
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1BONE MARROW TRANSPLANTATION WITH T-CELL-DEPLETED GRAFTS1986 · 17 citations
  2. 2Transfer to cyclophosphamide-treated mice of natural killer (NK) cells and in vivo natural reactivity against tumors.1981 · 89 citations
  3. 3The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin-21988 · 182 citations
  4. 4Graft-versus-leukemia reactions after bone marrow transplantation1990 · 2,778 citations
  5. 5Graft-versus-leukemia reactions after bone marrow transplantation1990 · 169 citations